Ana Catharina de Seixas Santos Nastri

Ana Catharina de Seixas Santos Nastri

Auto-generated profile, based on publicly available information

Ana Catharina de Seixas Santos Nastri

Division of Infectious Diseases, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo , São Paulo

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
APAna Maria Passos-Castilho
Ana Maria Passos-Castilho
VCValdemir Melechco Carvalho
Valdemir Melechco Carvalho
KCKarina Helena Morais Cardozo
Karina Helena Morais Cardozo
LKLuciana Kikuchi
Luciana Kikuchi
ACAline Lopes Chagas
Aline Lopes Chagas
CGCelso Francisco Hernandes Granato
Celso Francisco Hernandes Granato
Chronic hepatitis B (CHB) virus infection is a major cause of hepatocellular carcinoma (HCC), as late diagnosis is the main factor for the poor survival of patients. There is an urgent need for accurate biomarkers for early diagnosis of HCC. The aim of the study was to explore the serum lipidome profiles of hepatitis B-related HCC to identify potential diagnostic biomarkers. An ultraperformance liquid chromatography mass spectrometry (UPLC-MS) lipidomic method was used to characterize serum profiles from HCC (n = 32), liver cirrhosis (LC) (n = 30), CHB (n = 25), and healthy subjects (n = 34). Patients were diagnosed by clinical laboratory and imaging evidence and all presented with CHB while healthy controls had normal liver function and no infectious diseases. The UPLC-MS-based serum lipidomic profile provided more accurate diagnosis for LC patients than conventional alpha-fetoprotein (AFP) detection. HCC patients were discriminated from LC with 78 % sensitivity and 64 % specificity. In comparison, AFP showed sensitivity and specificity of 38 % and 93 %, respectively. HCC was differentiated from CHB with 100 % sensitivity and specificity using the UPLC-MS approach. Identified lipids comprised glycerophosphocolines, glycerophosphoserines and glycerophosphoinositols. UPLC-MS lipid profiling proved to be an efficient and convenient tool for diagnosis and screening of HCC in a high-risk population.

7 May 2022 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
ANAna Catharina Nastri
Ana Catharina Nastri
ADAmaro Duarte-Neto
Amaro Duarte-Neto
LCLuciana Vilas Boas Casadio
Luciana Vilas Boas Casadio
William SouzaWilliam Souza
William Souza
ICIngra M. Claro
Ingra M. Claro
ALAnna S. Levin
Anna S. Levin

25 November 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
CFClaudia Figueiredo-Mello
Claudia Figueiredo-Mello
LCLuciana Vilas Boas Casadio
Luciana Vilas Boas Casadio
VAVivian I. Avelino-Silva
Vivian I. Avelino-Silva
YHYeh-Li Ho
Yeh-Li Ho
JSJaques Sztajnbok
Jaques Sztajnbok
ALAnna S Levin
Anna S Levin
Introduction An ongoing outbreak of yellow fever (YF) has been reported in Brazil with 1261 confirmed cases and 409 deaths since July 2017. To date, there is no specific treatment available for YF. Recently published papers describing in vitro and animal models suggest a potential effect of antiviral drugs (approved for the treatment of hepatitis virus) against flaviviruses, including YF. The primary aim of this study is to analyse the effect of sofosbuvir on viral kinetics and clinical outcomes among patients presenting with YF. This is a multicentre open-label randomised controlled trial with 1:1 individual allocation, stratified by severity and by recruiting centre. Methods and analysis Adults with suspected or confirmed YF infection and symptoms lasting up to 15 days are screened. Eligible and consenting patients are randomised to receive oral sofosbuvir 400 mg daily for 10 days or to receive standard clinical care. Viral kinetics are measured daily and the reduction in YF plasma viral load from the sample at inclusion to 72 hours after randomisation will be compared between active and control groups. Clinical outcomes include severity meeting criteria for intensive care support, liver transplantation, in-hospital mortality and mortality within 60 days. Ethics and dissemination Ethics approval was obtained at the participating sites and at the national research ethics committee (CAAE 82673018.6.1001.0068). The trial has been submitted for ethical approval at additional potential recruiting centres. Results of the study will be published in journals and presented at scientific meetings. Trial registration Brazilian Clinical Trials Registry (RBR-93dp9n).

13 June 2022 in Clinics
Verified
Journal Article
Open access
MFMaristela p freire
Maristela p freire
MOMaura Salaroli Oliveira
Maura Salaroli Oliveira
MMMarcello Magri
Marcello Magri
BTBruno Melo Tavares
Bruno Melo Tavares
IMIgor Marinho
Igor Marinho
ALAnna S. Levin
Anna S. Levin
The aim of this study was to describe the incidence and risk factors for hospital readmission and infection during the months after COVID-19 hospital admission. This prospective study included adult patients who were hospitalized due to COVID-19 and had been discharged from April 2020 to August 2020. All patients had a medical evaluation with a structured questionnaire 6 to 11 months after hospital admission. The authors included only patients with confirmed COVID-19 by RT-PCR. Patients with pregnant/postpartum women, with a proven COVID-19 reinfection or incapable of answering the questionnaire were excluded. A total of 822 patients completed the follow-up assessment, and 68% reported at least one recurrent symptom related to COVID-19. The most frequent symptom was myalgia (42%). Thirty-two percent of patients visited an emergency room after COVID-19 hospitalization, and 80 (10%) patients required re-hospitalization. Risk factors for hospital readmission were orotracheal intubation during COVID-19 hospitalization (p = 0.003, OR = 2.14), Charlson score (p = 0.002, OR = 1.21), congestive heart failure (p = 0.005, OR = 2.34), peripheral artery disease (p = 0.06, OR = 2.06) and persistent diarrhea after COVID-19 hospitalization discharge (p = 0.02, OR = 1.91). The main cause of hospital readmission was an infection, 43 (54%). Pneumonia was the most frequent infection (29%). The presence of symptoms after six months of COVID-19 diagnosis was frequent, and hospital readmission was relatively high.

31 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
SCSamira Chuffi
Samira Chuffi
MGMichele S Gomes-Gouvea
Michele S Gomes-Gouvea
LCLuciana V. B. Casadio
Luciana V. B. Casadio
ANAna Catharina S. S. Nastri
Ana Catharina S. S. Nastri
MGMario P. Gonzalez
Mario P. Gonzalez
João Renato Rebello PinhoJoão Renato Rebello Pinho
João Renato Rebello Pinho
Outbreaks of hepatitis A may occur in countries of medium and high socioeconomic levels in which the population generally exhibits an increased susceptibility in young adults to this infection if they are not vaccinated against the hepatitis A virus (HAV). In Europe, an outbreak involved approximately 22 European countries with 4475 cases reported from 2016 to 2018; most of them were men who have sex with men (MSM). This outbreak expanded to North and South America, including Brazil, particularly in São Paulo city with 1547 reported cases from 2016 to 2019. In the present study, we characterized the HAV strains involved in the acute hepatitis A cases identified in the reference centers of São Paulo city during this outbreak. A total of 51 cases with positive anti-HAV IgM were included, 80.4% male, 68.6% of them between 20 and 40 years old and 41.7% MSM. HAV RNA was detected in 92% (47/51) of the cases. Subgenotype IA of HAV was identified and most of the strains were closely related to that isolated in outbreaks that occurred in different European countries in 2016. These results showed the epidemiological relation between these outbreaks and reinforce the need to implement vaccination against hepatitis A for the adult population, particularly for a population with a high-risk behavior.

17 March 2022 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
MFMaicon Falavigna
Maicon Falavigna
KBKarlyse Claudino Belli
Karlyse Claudino Belli
ABAlexandre Naime Barbosa
Alexandre Naime Barbosa
AZAlexandre Prehn Zavascki
Alexandre Prehn Zavascki
ANAna Catharina de Seixas Santos Nastri
Ana Catharina de Seixas Santos Nastri
CCCarlos Roberto Ribeiro de Carvalho
Carlos Roberto Ribeiro de Carvalho
Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil. A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method. Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation. To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments.